Here you can learn more about isotopic metallome, find our overviews, white papers, patents, third party research in support of our scientific stance, and many more...
Here you can learn more about isotopic metallome, find our overviews, white papers, patents, third party research in support of our scientific stance, and many more...
In Vitro Anticancer Activity of Light Stable Zinc Isotope (64Zn) Compounds
This publication presents evaluation of cytotoxic activity of our first therapeutic drug candidate based of light zinc isotope 64Zn enriched to >99% against MB16 melanoma and L1210 leukemia cells malignant cells.
First-in-Human Study of KLS-1 (64Zn L-Aspartate)
This publication presents our small, non-registrational, first-in-human "learning" study of our KLS-1 drug candidate (64Zn enriched to >99%) in patients with oncological and neurodegenerative diseases. The purpose of this study was to establish initial dose of KLS1 for treatment of patients with various pathologies prior to conducting full-scale registrational Phase 1 clinical trial.
Targeting Inflammation in Alzheimer's Disease With Isotopically Modified Zinc Complex
This white paper outlines our perspective on targeting systemic inflammation in Alzheimer's disease (AD) research and presents findings from our preclinical investigation in this area. The purpose of this study was to assess the effect of intravenous administration of novel investigational drug substance, 64Zn aspartate (KLS-1), on local and systemic inflammation and on cognitive parameters in rats with Aβ1-40-induced AD.
In Vitro Anticancer Activity of Light Stable Zinc Isotope (64Zn) Compounds
Inflammatory Hallmarks in 6-OHDA- and LPS-induced Parkinson's Disease in Rats
Inflammatory Hallmarks in 6-OHDA- and LPS-induced Parkinson's Disease in Rats
This publication presents a comparison of activation patterns of microglia/macrophage population and systemic inflammation indices in rats with 6-Hydroxydopamine (6-OHDA)- and Lipopolysaccharide (LPS)-induced animal models of Parkinson's Disease. This is essential for maximizing the translation of their potential to the clinic, as well as for developing putative anti-inflammatory neuroprotective agents.
Systemic Inflammation in Aβ1-40-induced Alzheimer’s Disease Model: New Translational Opportunities
Systemic Inflammation in Aβ1-40-induced Alzheimer’s Disease Model: New Translational Opportunities
Neuroinflammation is associated with the impairment of blood–brain barrier and leakage of inflammatory mediators into the periphery with developing systemic inflammatory responses. Systemic inflammation is considered one of the therapeutic targets for AD treatment that necessitates in-depth study of this phenomenon in appropriate non-transgenic animal models. This publication discusses inflammation as one of the therapeutic targets for treatment of Alzheimer's disease (AD.)